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Aim: To identify risk factors that inﬂuence weight loss in patients receiving radiotherapy.
Background: It is a well-known fact that cancer patients can be affected by malnutrition at
the  onset of the disease and during treatment due to the toxicity. Pretreatment weight loss
alone does not predict those who will need nutritional supplementation. Instead, a variety
of  nutritional and tumor related factors needs to be taken into account.
Material and methods: A retrospective study was conducted on 129 patients with different
tumor locations. Weight loss was evaluated during radiotherapy and one month after treat-
ment. The impact of age, ECOG, chemotherapy, pretreatment weight loss, tumor location,
previous surgery and TNM were analyzed. We  aimed to identify a high-risk group of patients
before starting treatment.
Results: The average net weight loss during radiotherapy and one month after treatment
for  this group of patients was 0.68 kg and 1.6 kg, respectively. Median weight loss during
radiotherapy was 2.6 kg for head and neck (HN) patients and 0.27 kg for other tumor sites
(p  = 0.028). Median weight loss one month after radiotherapy was 3.7 kg for HN patients
and  1.1 kg for the rest of the patients (p = 0.034). The median weight loss one month after
treatment was 3.2 kg for patients receiving chemotherapy and 0.5 kg for those patients who
did  not receive chemotherapy (p < 0.001). A regression analysis determined that HN tumor
location and the use of chemotherapy were independent risk factors.
Conclusions: Nutritional status must be monitored and managed before, during and after
treatment. A variety of nutritional and tumor-related factors must be considered. Accordingto  our results, head and neck tumors and the use of chemotherapy are the only two factors
considered statistically signiﬁcant. Because patients continue to lose weight after treatment,
we  recommend close surveillance after radiotherapy.
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1.  Background
Patients receiving radiotherapy and chemotherapy often have
a compromised nutritional status preceding and during treat-
ment due to irradiation of large areas of mucous membranes
and salivary glands. Toxicities such as nausea, vomiting,
diarrhea, anorexia or dysphagia can negatively affect the
nutritional status by decreasing food intake and/or absorp-
tion of nutrients.1,2 Considering the widespread prevalence of
malnutrition, prompt identiﬁcation is required, followed by an
appropriate, effective treatment.
Weight loss during treatment not only increases the risk of
adverse outcomes but also may interrupt the treatment, which
compromises tumor control.3,4 Therefore, dietetic interven-
tion should be considered in the treatment plan, especially
for head and neck (HN) patients.5–7 In short, a high number of
patients with cancer are affected by malnutrition; the occur-
rence of certain symptoms leads to an inadequate food intake.
Patients who have malnutrition can be managed with a vari-
ety of oral dietary approaches including dietary modiﬁcation,
counseling by a dietician and/or oral nutritional supplements
(ONS).8
2.  Aim
The aim of this study was to assess the previous nutritional
status of a cohort of 129 consecutive patients, to describe the
characteristics of these patients before receiving treatment,
and to detect which risk-factors may inﬂuence weight loss
during radiotherapy.
3. Materials  and  methods
The medical records of 129 consecutive patients were ret-
rospectively reviewed (July 2010 to December 2010). Ethical
approval was obtained for this study from the Cruces Univer-
sity Hospital. We  described our population, evaluated weight
loss (during radiotherapy and one month after treatment)
and analyzed any nutritional or disease related factors that
might inﬂuence weight loss during radiotherapy. In deciding
which factors were important, we concentrated on those asso-
ciated with malnutrition, including pretreatment weight loss,
tumor site and stage, age, inﬂuence of chemotherapy, previous
surgery and performance status.
3.1.  Nutritional  considerations
Patients received individualized dietary counseling based on
regular foods. All patients were encouraged to eat their nor-
mal  diet ad libitum and were given nutritional counseling
that included recommendations of a full liquid, puréed, or
soft diets using common household foods when appropriate.
Dietary recommendations were adjusted to control associated
symptomatologies caused by tumor or treatment toxicity. No
routine nutritional supplements were employed.iotherapy 1 7 ( 2 0 1 2 ) 269–275
3.2. Nutritional  assessment
At the ﬁrst clinical visit, the medical staff registered the follow-
ing information: patient’s age, gender, cancer location, TNM
stage, surgery prior to radiotherapy, chemotherapy protocol.
All patients also had a nutritional assessment at their ﬁrst
clinic visit. Baseline body weight was deﬁned as that measured
at the time of initial consultation, and a physician assessed the
patient’s performance status at baseline using the ECOG (East-
ern Cooperative Oncology Group) scale. Nutritional assess-
ment (body weight and dietetic counseling) was performed
at pretreatment and weekly during radiation therapy. Self-
reported weight loss within the six months preceding enroll-
ment in the study was recorded from the ﬁrst clinical visit.
All patients were treated 5 days per week with continuous-
course, once-daily radiation therapy. The patients’ body
weight was obtained, and nutritional counseling was provided
at least once weekly during the course of radiation therapy.
Patients were typically seen 4 weeks after radiation ther-
apy was completed. At this time, body weight was obtained
and compared with baseline weight. A blood count, including
serum albumin, was obtained at pretreatment and at the end
of radiotherapy.
All patients were considered eligible, regardless of whether
the proposed radiotherapy was primary, adjuvant to surgery,
combined with chemotherapy or of palliative intent.
In summary, this study aims to describe the nutritional
status of a cohort of patients before starting treatment
and to evaluate changes in their nutritional status (body
weight) throughout radiotherapy. In our opinion, there are
factors that may inﬂuence weight loss during radiotherapy.
For patients undergoing radiotherapy, tumor location or type
of antineoplasic treatment should be considered as a risk
for malnutrition. Our aim is to identify a high-risk group of
patients before starting treatment.
3.3.  Statistical  analysis
Continuous variables are expressed using a mean and stan-
dard deviation. Categorical variables are described as numbers
and percentages.
Student’s t-test and Mann–Whitney U-test were used to
compare the following variables: weight loss during radiother-
apy, weight loss one month after radiotherapy with previous
surgery, TNM, chemotherapy, serum albumin level, ECOG and
tumor location.
Student’s t-test or Mann–Whitney U-test was performed
depending on the distribution of the variable.
A univariate and multivariate linear regression model was
developed to determine which variables were associated with
weight loss.
Statistical signiﬁcance was set for a p value less than .05.
Data were analyzed using statistical Package for the Social
Sciences (SPSS, version 19.0).
4.  Results4.1.  Patient  characteristics
The results of 129 consecutive patients were retrospectively
reviewed.
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Table 1 – Distribution of tumor location.
N %
Head and neck 24 18.8
Brain 3 2.3
Rectum 13 10.2
Histiocytoma 1 0.8
Lymphoma 1 0.8
Breast 29 22.7
Prostate 20 15.6
Lung 21 16.4
Sarcoma 1 0.8
Gynecological 13 10.2
Bladder 2 1.6
Unknown 1 0.8
Total 129 100
N = number of patients and % = percentage.
Table 2 – Descriptive statistics.
N X˜ ±SD
Age 124 62.15 11.48
Baseline weight (kg) 129 73.32 14.39
Height (cm) 125 163 8
Weight loss (%) 117 1.75 3.82
Serum albumin baseline level 120 4.26 0.34
Weight week 1 126 73.62 14.29
Weight week 2 127 73.32 14.34
Weight week 3 126 73.30 14.40
Weight week 4 121 72.85 14.38
Weight week 5 111 73.28 14.13
Weight week 6 64 73.52  12.50
Weight week 7 30  76.23 13.28
Weight week 8 11 79.45 13.57
Serum albumin level after
radiotherapy
123 4.18 0.43
Weight loss (kg) six months
preceding treatment
117 1.25 2.74
Weight loss one month after
radiotherapy
127 1.60 3.85
Weight loss during
radiotherapy
129  0.68 3.01
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Table 3 – Pretreatment weight loss.
Pretreatment WL  N %
No loss 89 77.6
<5% 11 9.5
5–10% 9 7.8
>10% 7 6.0
Total 116 100
N = number of patients, WL = weight loss, and % = percentage.
Table 4 – Pretreatment weight loss related to tumor
location.
Tumor location Pretreatment WL  N %
Head and neck
No  loss 14 63.6
<5% 4 18.2
5–10% 3 13.6
>10% 1 4.5
Total 22 100
Brain No loss 3 100
Rectum
No loss 7 53.8
<5% 3 23.1
>10% 3 23.1
Total 13 100
Sarcoma No loss 1 100
Hystiocitoma Unknown 1 100
Lymphoma No loss 1 100
Breast
No loss 23 85.2
<5% 2 7.4
5–10% 1 3.7
>10% 1 3.7
Total 27 100
Prostate No loss 17 100
Lung
No loss 10 62.5
<5% 1 6.3
5–10% 2 12.5
>10% 3 18.8
Total 16 100
Gynecological
No loss 11 84.6
>10% 2 15.4
Total 13 100
Bladder
No loss 1 50
<5% 1 50
Total 2 100
N = number of patients, WL = weight loss, and % = percentage.
Table 5 – Median weight loss during radiotherapy and
one month after treatment related to pretreatment
weight loss.
Weight loss (%) MWL  (kg)
MWL during radiotherapy
<5  0.6782
≥5 0.8750
MWL one month after
treatment
<5  1.7040
≥5 1.1250
MWL = median weight loss, < = less than, and ≥ = equal or moreX˜ = mean,  N = number of patients, and SD = standard deviation.
Of the 129 patients, 61.24% (n = 79) were male, and 38.75%
n = 50) were female, with a mean age of 62 years (range 29–87).
he distribution of tumor location and descriptive statistics
re shown in Tables 1 and 2, respectively. No prophylactic
asogastric tube or gastrostomy was placed in any patient.
.2.  Pretreatment  weight  loss
retreatment weight loss was evaluated globally and accord-
ng to different tumor locations to assess its effect on weight
oss during radiotherapy and one month after treatment
Tables 3 and 4). The inﬂuence of pretreatment weight loss
reater than 5% was evaluated (Table 5). There was no statis-
ically signiﬁcant difference between patients that lost more
han 5% of their weight or less than 5% of their weight before
adiotherapy and the median weight lost during radiotherapy
r one month after treatment.
than).
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Table 6 – Chemotherapy according to tumor location.
Tumor location QT N %
Head
and
neck
No  13 59.1
Yes 9 40.9
Total 22 100.0
Brain Yes 3 100.0
Colo-
rectum
No 1 8.3
Yes 11 91.7
Total 12 100.0
Hystiocitoma Yes 1 100.0
Lymphoma Yes 1 100.0
Breast
No 12 52.2
Yes 11 47.8
Total 23 100.0
Prostate No 17 100.0
Lung
No 5 29.4
Yes 12 70.6
Total 17 100
Sarcomas No 1 100
Gynecological
No 4 30.8
Yes 9 69.2
Total 13 100
Bladder Yes 1 100
N = number of patients, QT = chemotherapy, and % = percentage.272  reports of practical oncology an
4.3. Weight  loss  during  and  after  treatment
Patient weights at the start and end of treatment were used to
calculate body weight loss during radiotherapy. Weight loss
was evaluated weekly during radiotherapy and one month
after treatment. A total of 49.6% of patients lost weight
throughout radiotherapy, with a median weight loss during
treatment of 2.85 kg (SD ± 2.72). This weight loss corresponds
to a 3.63% (SD ± 3.01) net reduction from their baseline weight.
One month after treatment, 63% of patients lost weight with
a median weight loss of 3.47 kg (SD ± 3.62), which corresponds
to a 4.42% (SD ± 3.90) net reduction from their baseline weight.
Overall, the average net weight loss for this group of 129
patients from the ﬁrst to last day of radiation therapy (dur-
ing treatment) and one month after treatment in this study
was 0.68 kg and 1.6 kg, respectively.
4.4.  Previous  surgery
The inﬂuence of previous surgery on weight loss was ana-
lyzed. Weight loss during radiotherapy was 0.6 kg (SD ± 2.75)
for patients that underwent surgery before radiotherapy and
1.13 kg (SD ± 3.43) for patients that did not undergo surgery
before radiation treatment. This difference was not statisti-
cally signiﬁcant.
4.5.  Age
There were 55 patients (45.1%) older than 65 years and 67
(54.9%) patients younger than 65 years. Median weight loss
during radiotherapy in patients over 65 years old was 1.98 kg
(SD ± 3.90), whereas patients below 65 lost 1.29 kg (SD ± 3.70).
We did not ﬁnd signiﬁcant differences in weight loss during
treatment or one month after treatment according to age.
4.6.  ECOG
In respect to performance status, 86 patients were classiﬁed as
ECOG 0 (73.5%) and 31 as ECOG 1 (26.5%). Median weight loss
during radiation therapy for patients with ECOG 0 was 0.3 kg
(SD ± 2.71), whereas median weight loss for patients with
ECOG 1 was of 1.8 kg (SD ± 3.77), (p = 0.011). Median weight loss
one month after treatment was 1.16 kg (SD ± 3.67) for patients
categorized as ECOG 0 and 3.02 kg (SD ± 4.22) for patients with
ECOG 1, (p = 0.016).
4.7.  Tumor  location
The inﬂuence of tumor location was analyzed by comparing
median weight loss during radiotherapy between HN patients
and other tumor sites. Median weight loss during radiotherapy
was 2.64 kg (SD ± 4.75) for HN patients and 0.27 kg (SD ± 2.24)
for all other patients (p = 0.028). The median weight loss
one month after radiotherapy was 3.72 kg (SD ± 5.46) for HN
patients and 1.1 kg (SD ± 3.19) for other tumor sites (p = 0.034).
A similar comparison was made between patients with lung
cancer and other tumor sites. Median weight loss during radio-
therapy was 1.04 kg (SD ± 3.01) for lung cancer patients and
0.65 kg (SD ± 3.01) for all others. Median weight loss one month
after treatment was 2.9 kg (SD ± 5.38) for lung cancer patientsand 1.3 kg (SD ± 3.43) for patients with other tumor sites. These
differences were not statistically signiﬁcant. There were small
clinical differences in weight loss between patients with col-
orectal cancer and other cancer types, but no statistically
signiﬁcant differences were found.
4.8.  TNM
Forty-eight patients (37.2%) were classiﬁed as stage I and II,
and 47 patients (36.4%) had locally advanced disease (stages III
and IV). Weight loss during radiotherapy was 0.4 kg (SD ± 2.35)
for stages I and II patients and 1.5 kg (SD ± 3.79) for stages III
and IV (p = 0.22). Weight loss one month after treatment was
0.9 kg (SD ± 2.72) and 2.6 kg (SD ± 4.93) for stages I–II and II–IV,
respectively (p = 0.20).
4.9.  Chemotherapy
A total of 58 (51.3%) patients received chemotherapy (con-
comitant scheme in 30.1%) and 53 (48.6%) did not. The use
of chemotherapy according to tumor location is described
in Table 6. Median weight loss during treatment was 1.8 kg
(SD ± 3.32) for patients who received chemotherapy and
0.02 kg (SD ± 2.56) for patients that did not (p < 0.001).
The median weight loss one month after treatment was
3.2 kg (SD ± 4.30) for patients who received chemotherapy and
0.5 kg (SD ± 3.03) for patients that did not (p < 0.001).Weight loss in patients receiving chemotherapy according
to tumor location is shown in Table 7.
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Table 7 – Weight loss in patients receiving chemotherapy according to tumor location.
Tumor location WL  (kg) N Median WL (kg) SD
Head and neck
WL  during radiotherapy 9 6.13 2.95
WL one month after 9 7.63 2.60
Brain
WL during radiotherapy 3 0.86 2.40
WL one month after 3 1.83 2.81
Colo-rectum
WL during radiotherapy 11 0.89 2.92
WL one month after 10 1.85  3.67
Hystiocitoma
WL during radiotherapy 1 −2.10
WL one month after 1 0.20
Lymphoma
WL during radiotherapy 1 −3.10
WL one month after 1 −3.30
Breast
WL during radiotherapy 11 0.07 1.03
WL one month after 0.92 1.52
Lung
WL during radiotherapy 12 1.70 3.84
WL one month after 12 4.68 6.36
Gynecological
WL during radiotherapy 9 2.11 1.98
WL one month after 8 2.38 1.47
Bladder
WL during radiotherapy 1 3.70
WL one month after 1 4.20
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dWL = weight loss in kg and SD = standard deviation.
.10. Albumin
edian serum albumin levels for pretreatment and posttreat-
ent were 4.27 g/dl and 4.18 g/dl, respectively. These values
ere compared, but no statistically signiﬁcant differences
ere found.
The signiﬁcant factors identiﬁed on univariate analysis
ere HN tumor location, ECOG and the use of chemotherapy.
hen multivariate analysis was performed, only chemother-
py and HN area were considered independent risk factors.
here were no other factors considered statistically signiﬁ-
ant.
.  Discussion
t is a well-known fact that cancer patients can be affected
y malnutrition at the onset of the disease and during treat-
ent due to the toxicity. Pretreatment weight loss alone does
ot predict those who will need nutritional supplementation.
nstead, a variety of nutritional and tumor related factors
eeds to be taken into account. For example, in HN can-
er patients, radiotherapy can have a compounding effect on
utritional status.9
Understanding this relationship, we aimed to identify
hose factors that may have inﬂuenced the patients’ weight
oss during radiation therapy.
Malnutrition in oncology patients has an impact on clinical
volution and therapeutic adherence.10 Ravasco et al. exten-
ively studied the effectiveness of nutritional counseling and
ound an improvement in the quality of life in HN cancer
atients when receiving counseling instead of supplements
ithout any advice.11 Ravasco et al. also demonstrated that
ietary counseling improves outcomes in colorectal cancer
atients undergoing radiotherapy. Nutritional counseling was
hown to be as effective as high energy and high protein ONS
uring radiotherapy.12 Therefore, general dietary recommen-
ations for speciﬁc cancers and recommendations accordingto therapy type are always given in our nutritional protocol for
symptom control in this patient population (anorexia, nausea,
dysphagia, mucositis, etc.). In general, we recommend a bal-
anced and healthy diet according to their symptoms to help
the patient achieve adequate intake.
HN patients clearly lost more  weight (at least three times
more) during radiotherapy and one month after treatment
as compared to other pathologies. Therefore, this evidence
further emphasizes the role of cancer location in nutrition,
as previously reported.13–15 No statistically signiﬁcant differ-
ences were found for other tumor locations. This ﬁnding is
particularly relevant because HN cancer patients have addi-
tional nutritional deﬁcits. The anatomical location of the
tumor itself may cause dysphagia, and radiation therapy
causes mucosal reactions that may further limit oral intake.
Mangar et al. found that an advanced tumor stage could be
used to identify patients at high risk of malnutrition during
radiation therapy.9 However, weight change had no signiﬁcant
association with advanced stage in our study. Approximately
60% of patients had no available TNM classiﬁcation; thus, a
deﬁnitive conclusion cannot be reached due to the small num-
ber of patients with an available classiﬁcation.
In recent years, the role of malnutrition as a predictor of
cancer survival has received considerable attention. A serum
albumin level provides an estimate of visceral protein func-
tion. A depressed serum albumin has been associated with
a greater incidence of morbidity and mortality in hospital-
ized patients. Several studies report similar ﬁndings.2,16,17
Recently, Gupta and Lis performed a systematic review to iden-
tify epidemiologic studies of the relationship between serum
albumin and cancer survival. This review concluded that pre-
treatment serum albumin levels provide useful prognostic
information for cancer18; therefore, maintaining an accept-
able serum albumin level is desirable. However, we  did not
ﬁnd a signiﬁcant decrease in median serum albumin level
between pretreatment and posttreatment in this study. This
result might be explained by the low median weight loss dur-
ing treatment.
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There is a lack of evidence-based data regarding toxic-
ity in the elderly patients, especially in the ﬁeld of radiation
therapy.19 In the present study, surprisingly, weight loss
showed no signiﬁcant association with age. Other authors
have reported the opposite.9 In our study, the percentage of
patients over 65 years was 45.1%. The inﬂuence of increasing
age on weight loss was analyzed, but age was not found to be
an inﬂuential factor in weight loss.
Patients receiving chemotherapy had a signiﬁcant weight
loss during treatment and an increased weight loss one
month after treatment when compared to patients that did
not receive chemotherapy. Because of this ﬁnding, we  con-
sider chemotherapy to be a major risk factor for weight loss.
It is noteworthy that the use of chemo-radiotherapy may
increase the severity of mucosal reactions, nausea and vomit-
ing; thus, contributing to the increased weight loss of patients
undergoing radiotherapy.9 The radiosensitization effect of
chemotherapy leads to increased acute toxicities that prevent
effective oral feeding. Ineffective oral feeding leads to severe
weight loss in a signiﬁcant number of patients.
The inﬂuence of surgery previous to radiation therapy in
weight loss was analyzed, and there was a trend in weight loss
during radiation therapy for patients that underwent previous
surgery; however, this difference was not found statistically
signiﬁcant.
It has been published previously that low performance sta-
tus can be used in a predictive manner to identify patients at
high risk of malnutrition during radiation therapy.9 In general,
these differences have been found by comparing ECOG score
0–1 vs. ECOG 2–3. However, we could not identify low ECOG
scores (>2) as a risk factor. This result occurred because 100%
of patients had an ECOG score of 0–1. Otherwise, there was
a clinical difference in weight loss during radiotherapy and
one month after treatment between patients categorized as
ECOG 1 vs. ECOG 0. This difference was found signiﬁcant in
univariate analysis but not in multivariate analysis.
This study provides a description of the baseline nutri-
tional status of patients before starting radiochemotherapy
and the inﬂuence of parameters such as age, pretreatment
weight loss, chemotherapy, prior surgery, TNM, and cancer
location on the trends of weight loss during treatment. Tumors
in the head and neck area and the use of chemotherapy were
the only two  risk factors considered statistically signiﬁcant in
this study. Patient outcomes may be optimized if nutritional
status is adequately monitored and managed before and dur-
ing treatment. Because patients continue to lose weight after
treatment, patients should be watched closely after complet-
ing radiotherapy.
6.  Conclusions
A nutritional assessment is essential prior to radiation
therapy. Decisions about the treatment of disease-related
malnutrition should be guided by evidence where possible.
Nutritional status and risk factors, such as tumor location
(especially head and neck) and the use of chemotherapy,
should be evaluated because these factors can inﬂuence
weight loss during radiotherapy even if patients do not present
with weight loss at pretreatment evaluation.
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